Laura James
Concepts (561)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acetaminophen | 60 | 2024 | 283 | 12.510 |
Why?
| Analgesics, Non-Narcotic | 26 | 2024 | 117 | 5.070 |
Why?
| Drug Overdose | 16 | 2024 | 163 | 3.100 |
Why?
| Liver | 24 | 2024 | 1116 | 2.970 |
Why?
| Hepatocytes | 15 | 2018 | 182 | 2.370 |
Why?
| Liver Failure, Acute | 12 | 2024 | 54 | 2.360 |
Why?
| Liver Regeneration | 9 | 2019 | 49 | 2.000 |
Why?
| Alanine Transaminase | 17 | 2023 | 124 | 1.320 |
Why?
| MicroRNAs | 4 | 2020 | 355 | 1.290 |
Why?
| Adolescent | 45 | 2024 | 6390 | 1.190 |
Why?
| Male | 84 | 2024 | 25399 | 1.180 |
Why?
| Proton Pump Inhibitors | 7 | 2024 | 85 | 1.180 |
Why?
| Acetylcysteine | 13 | 2019 | 100 | 1.180 |
Why?
| Cytochrome P-450 CYP2E1 | 4 | 2020 | 113 | 1.170 |
Why?
| Mitochondria, Liver | 10 | 2015 | 70 | 1.140 |
Why?
| Oxidative Stress | 12 | 2023 | 771 | 1.080 |
Why?
| Cytochrome P-450 CYP3A | 3 | 2020 | 78 | 1.070 |
Why?
| Child | 42 | 2024 | 6851 | 1.060 |
Why?
| Humans | 103 | 2024 | 50208 | 0.980 |
Why?
| Chromatography, High Pressure Liquid | 10 | 2016 | 327 | 0.930 |
Why?
| Child, Preschool | 29 | 2024 | 3883 | 0.930 |
Why?
| Cytokines | 8 | 2012 | 613 | 0.890 |
Why?
| Attitude | 2 | 2021 | 69 | 0.880 |
Why?
| Asthma | 4 | 2022 | 280 | 0.880 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2012 | 56 | 0.880 |
Why?
| Female | 63 | 2024 | 26635 | 0.840 |
Why?
| Animals | 41 | 2023 | 13246 | 0.830 |
Why?
| Proteins | 4 | 2016 | 345 | 0.820 |
Why?
| Rape | 1 | 2022 | 14 | 0.820 |
Why?
| Vitamin D Deficiency | 1 | 2022 | 44 | 0.800 |
Why?
| Crime Victims | 1 | 2022 | 33 | 0.800 |
Why?
| Sex Offenses | 1 | 2022 | 72 | 0.750 |
Why?
| Health Facilities | 1 | 2021 | 42 | 0.730 |
Why?
| Inflammation | 3 | 2020 | 604 | 0.710 |
Why?
| Cysteine | 7 | 2024 | 50 | 0.710 |
Why?
| Health Services Accessibility | 2 | 2021 | 399 | 0.700 |
Why?
| Mice | 29 | 2023 | 5759 | 0.690 |
Why?
| Naphthalenes | 9 | 2018 | 121 | 0.690 |
Why?
| Cytochrome P-450 CYP1A2 | 4 | 2020 | 39 | 0.690 |
Why?
| Indoles | 9 | 2018 | 278 | 0.680 |
Why?
| Vascular Endothelial Growth Factor A | 3 | 2011 | 202 | 0.670 |
Why?
| Liver Diseases | 4 | 2023 | 78 | 0.670 |
Why?
| Bronchoconstriction | 1 | 2019 | 6 | 0.660 |
Why?
| Mitochondria | 2 | 2020 | 404 | 0.650 |
Why?
| 2-Pyridinylmethylsulfinylbenzimidazoles | 4 | 2018 | 19 | 0.630 |
Why?
| Aspartate Aminotransferases | 8 | 2015 | 45 | 0.620 |
Why?
| Bronchodilator Agents | 1 | 2019 | 73 | 0.610 |
Why?
| Radius | 1 | 2018 | 27 | 0.600 |
Why?
| Immunoassay | 1 | 2016 | 20 | 0.560 |
Why?
| Aryl Hydrocarbon Hydroxylases | 4 | 2014 | 74 | 0.560 |
Why?
| Serum | 1 | 2016 | 32 | 0.550 |
Why?
| Anti-Bacterial Agents | 6 | 2023 | 747 | 0.550 |
Why?
| Gastroesophageal Reflux | 4 | 2018 | 49 | 0.540 |
Why?
| Dose-Response Relationship, Drug | 12 | 2019 | 1378 | 0.540 |
Why?
| Infant | 21 | 2022 | 3563 | 0.520 |
Why?
| Mice, Inbred C57BL | 15 | 2019 | 1819 | 0.510 |
Why?
| Cystic Fibrosis | 1 | 2018 | 149 | 0.510 |
Why?
| Young Adult | 16 | 2021 | 3981 | 0.500 |
Why?
| Reactive Nitrogen Species | 3 | 2015 | 22 | 0.500 |
Why?
| HMGB1 Protein | 2 | 2021 | 17 | 0.500 |
Why?
| Keratin-18 | 2 | 2021 | 15 | 0.500 |
Why?
| Lung | 1 | 2019 | 490 | 0.500 |
Why?
| Proliferating Cell Nuclear Antigen | 4 | 2019 | 75 | 0.500 |
Why?
| Bile Acids and Salts | 1 | 2015 | 76 | 0.500 |
Why?
| Mass Spectrometry | 4 | 2014 | 301 | 0.480 |
Why?
| Tyrosine | 4 | 2007 | 95 | 0.480 |
Why?
| Mice, Inbred Strains | 7 | 2019 | 161 | 0.480 |
Why?
| Isoniazid | 1 | 2014 | 37 | 0.460 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 122 | 0.460 |
Why?
| Carnitine | 1 | 2014 | 62 | 0.450 |
Why?
| Disease Models, Animal | 7 | 2020 | 1458 | 0.440 |
Why?
| Autoantibodies | 1 | 2014 | 116 | 0.440 |
Why?
| Trifluoperazine | 1 | 2012 | 6 | 0.420 |
Why?
| Sensitivity and Specificity | 9 | 2016 | 863 | 0.420 |
Why?
| Viperidae | 1 | 2012 | 5 | 0.410 |
Why?
| Crotalid Venoms | 1 | 2012 | 9 | 0.410 |
Why?
| Tomography, X-Ray Computed | 1 | 2018 | 1161 | 0.410 |
Why?
| Antivenins | 1 | 2012 | 11 | 0.410 |
Why?
| Anti-Ulcer Agents | 3 | 2007 | 21 | 0.410 |
Why?
| Immunoglobulin Fragments | 1 | 2012 | 15 | 0.410 |
Why?
| Snake Bites | 1 | 2012 | 16 | 0.410 |
Why?
| Adult | 21 | 2024 | 13324 | 0.400 |
Why?
| Echinomycin | 1 | 2011 | 6 | 0.400 |
Why?
| Hospitalization | 4 | 2017 | 655 | 0.390 |
Why?
| Cannabinoids | 5 | 2013 | 105 | 0.380 |
Why?
| Half-Life | 6 | 2019 | 87 | 0.380 |
Why?
| Spider Venoms | 1 | 2011 | 6 | 0.380 |
Why?
| Hypersensitivity | 1 | 2012 | 77 | 0.380 |
Why?
| Necrosis | 6 | 2019 | 178 | 0.380 |
Why?
| Enzyme Inhibitors | 5 | 2019 | 386 | 0.380 |
Why?
| Phosphoric Diester Hydrolases | 1 | 2011 | 30 | 0.380 |
Why?
| Middle Aged | 17 | 2024 | 12206 | 0.370 |
Why?
| Indocyanine Green | 1 | 2010 | 34 | 0.370 |
Why?
| Prospective Studies | 11 | 2021 | 2379 | 0.350 |
Why?
| Macrolides | 3 | 2022 | 16 | 0.350 |
Why?
| Models, Biological | 7 | 2024 | 723 | 0.340 |
Why?
| Methamphetamine | 3 | 2013 | 200 | 0.340 |
Why?
| Metabolomics | 3 | 2015 | 125 | 0.330 |
Why?
| Central Nervous System Stimulants | 3 | 2013 | 213 | 0.330 |
Why?
| Triazoles | 3 | 2022 | 109 | 0.330 |
Why?
| Protein Binding | 5 | 2017 | 665 | 0.320 |
Why?
| Homeostasis | 3 | 2020 | 201 | 0.310 |
Why?
| Chemokines | 2 | 2010 | 78 | 0.300 |
Why?
| Research Subjects | 2 | 2019 | 49 | 0.300 |
Why?
| Chemokine CCL2 | 2 | 2005 | 71 | 0.300 |
Why?
| Community-Based Participatory Research | 2 | 2021 | 200 | 0.300 |
Why?
| Imines | 3 | 2019 | 12 | 0.290 |
Why?
| Poisoning | 2 | 2006 | 25 | 0.290 |
Why?
| Benzoquinones | 3 | 2019 | 29 | 0.290 |
Why?
| Area Under Curve | 8 | 2019 | 178 | 0.280 |
Why?
| Arkansas | 6 | 2024 | 1985 | 0.280 |
Why?
| Interleukin-6 | 3 | 2012 | 265 | 0.280 |
Why?
| Tandem Mass Spectrometry | 6 | 2018 | 231 | 0.280 |
Why?
| Interleukin-8 | 3 | 2012 | 86 | 0.280 |
Why?
| Pandemics | 2 | 2022 | 562 | 0.280 |
Why?
| Caustics | 1 | 2006 | 5 | 0.280 |
Why?
| Signal Transduction | 5 | 2019 | 1622 | 0.280 |
Why?
| Burns, Chemical | 1 | 2006 | 9 | 0.270 |
Why?
| Hypoxia-Inducible Factor 1 | 1 | 2006 | 3 | 0.270 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 22 | 0.270 |
Why?
| Cell Death | 4 | 2020 | 182 | 0.270 |
Why?
| Cross-Sectional Studies | 3 | 2022 | 1554 | 0.270 |
Why?
| Antidotes | 4 | 2011 | 29 | 0.260 |
Why?
| Infant, Premature | 4 | 2016 | 319 | 0.260 |
Why?
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2005 | 40 | 0.250 |
Why?
| Liver Function Tests | 2 | 2002 | 47 | 0.250 |
Why?
| Gene Expression Regulation | 3 | 2016 | 979 | 0.250 |
Why?
| Predictive Value of Tests | 5 | 2016 | 905 | 0.250 |
Why?
| Reactive Oxygen Species | 3 | 2015 | 408 | 0.250 |
Why?
| Peroxynitrous Acid | 2 | 2007 | 32 | 0.250 |
Why?
| Infant, Newborn | 10 | 2018 | 2766 | 0.250 |
Why?
| Cytochrome P-450 Enzyme System | 3 | 2015 | 195 | 0.240 |
Why?
| Up-Regulation | 4 | 2018 | 453 | 0.240 |
Why?
| Glutathione | 4 | 2023 | 296 | 0.240 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2024 | 48 | 0.230 |
Why?
| Blood Pressure Monitoring, Ambulatory | 2 | 2015 | 36 | 0.230 |
Why?
| Ion Channels | 1 | 2004 | 76 | 0.230 |
Why?
| Immunohistochemistry | 3 | 2012 | 978 | 0.230 |
Why?
| Gastric Acidity Determination | 1 | 2003 | 12 | 0.230 |
Why?
| Biotransformation | 4 | 2015 | 85 | 0.230 |
Why?
| Aminoglycosides | 1 | 2023 | 18 | 0.230 |
Why?
| Chromatography, Liquid | 6 | 2018 | 225 | 0.230 |
Why?
| Glucuronosyltransferase | 3 | 2017 | 124 | 0.220 |
Why?
| Medication Adherence | 1 | 2024 | 130 | 0.210 |
Why?
| Diagnosis, Differential | 4 | 2024 | 1043 | 0.210 |
Why?
| Administration, Oral | 7 | 2018 | 434 | 0.210 |
Why?
| Pilot Projects | 4 | 2021 | 697 | 0.210 |
Why?
| Aged | 7 | 2024 | 9405 | 0.210 |
Why?
| Granzymes | 2 | 2020 | 11 | 0.210 |
Why?
| Vitamins | 1 | 2022 | 64 | 0.210 |
Why?
| Membrane Glycoproteins | 1 | 2003 | 246 | 0.210 |
Why?
| Digestive System | 1 | 2002 | 15 | 0.200 |
Why?
| Pneumonia, Bacterial | 1 | 2022 | 27 | 0.200 |
Why?
| Community-Acquired Infections | 1 | 2022 | 39 | 0.200 |
Why?
| Designer Drugs | 2 | 2013 | 28 | 0.200 |
Why?
| Obesity | 2 | 2022 | 1108 | 0.200 |
Why?
| Retrospective Studies | 9 | 2024 | 6134 | 0.200 |
Why?
| Gastrointestinal Agents | 1 | 2002 | 33 | 0.200 |
Why?
| Vitamin D | 1 | 2022 | 88 | 0.200 |
Why?
| Phosphatidic Acids | 2 | 2019 | 8 | 0.200 |
Why?
| Anti-Infective Agents | 2 | 2013 | 95 | 0.190 |
Why?
| United States | 7 | 2022 | 4874 | 0.190 |
Why?
| Photography | 1 | 2021 | 32 | 0.190 |
Why?
| Microsomes, Liver | 4 | 2015 | 186 | 0.190 |
Why?
| Sexual Behavior | 1 | 2022 | 117 | 0.190 |
Why?
| Dried Blood Spot Testing | 2 | 2018 | 5 | 0.190 |
Why?
| Metabolic Clearance Rate | 5 | 2018 | 69 | 0.190 |
Why?
| Universities | 1 | 2022 | 162 | 0.190 |
Why?
| Healthcare Disparities | 1 | 2024 | 268 | 0.190 |
Why?
| Oxidation-Reduction | 6 | 2023 | 320 | 0.190 |
Why?
| Gastrointestinal Diseases | 1 | 2002 | 126 | 0.180 |
Why?
| Bayes Theorem | 3 | 2012 | 109 | 0.180 |
Why?
| Aged, 80 and over | 4 | 2021 | 3154 | 0.180 |
Why?
| Hydroxyurea | 1 | 2020 | 30 | 0.180 |
Why?
| Substance-Related Disorders | 3 | 2022 | 601 | 0.170 |
Why?
| Polymorphism, Genetic | 2 | 2018 | 181 | 0.170 |
Why?
| Heart Arrest | 1 | 2022 | 151 | 0.170 |
Why?
| Students | 1 | 2022 | 211 | 0.170 |
Why?
| Cell Line | 3 | 2017 | 1021 | 0.170 |
Why?
| Histamine H2 Antagonists | 3 | 2005 | 26 | 0.170 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2022 | 550 | 0.170 |
Why?
| Statistics, Nonparametric | 2 | 2011 | 193 | 0.170 |
Why?
| Lipids | 1 | 2020 | 148 | 0.170 |
Why?
| Recombinant Proteins | 4 | 2018 | 487 | 0.170 |
Why?
| Hepatic Veno-Occlusive Disease | 1 | 2019 | 10 | 0.170 |
Why?
| Binding Sites | 2 | 2017 | 375 | 0.170 |
Why?
| Prothrombin Time | 3 | 2005 | 18 | 0.170 |
Why?
| Stress, Physiological | 1 | 2020 | 170 | 0.170 |
Why?
| Glycerol-3-Phosphate O-Acyltransferase | 1 | 2019 | 5 | 0.170 |
Why?
| Mice, Knockout | 4 | 2011 | 846 | 0.160 |
Why?
| Carbachol | 1 | 2019 | 27 | 0.160 |
Why?
| ortho-Aminobenzoates | 1 | 2019 | 7 | 0.160 |
Why?
| Respiratory Hypersensitivity | 1 | 2019 | 17 | 0.160 |
Why?
| Child, Hospitalized | 1 | 2019 | 30 | 0.160 |
Why?
| Liver Cirrhosis | 1 | 2021 | 219 | 0.160 |
Why?
| Time Factors | 5 | 2013 | 2922 | 0.160 |
Why?
| Organ Culture Techniques | 1 | 2019 | 48 | 0.160 |
Why?
| Case-Control Studies | 3 | 2018 | 1126 | 0.160 |
Why?
| Disclosure | 1 | 2019 | 39 | 0.160 |
Why?
| Drug Administration Schedule | 4 | 2021 | 377 | 0.160 |
Why?
| Bacterial Infections | 2 | 2017 | 96 | 0.160 |
Why?
| Body Weight | 3 | 2018 | 512 | 0.160 |
Why?
| Cannabidiol | 1 | 2019 | 38 | 0.160 |
Why?
| Hepatitis, Viral, Human | 1 | 2018 | 6 | 0.160 |
Why?
| Health Status Disparities | 1 | 2021 | 194 | 0.160 |
Why?
| Research Personnel | 1 | 2019 | 66 | 0.160 |
Why?
| Oropharynx | 2 | 2009 | 13 | 0.160 |
Why?
| Albuterol | 1 | 2019 | 54 | 0.160 |
Why?
| Phosphatidate Phosphatase | 1 | 2018 | 11 | 0.150 |
Why?
| Ampicillin | 1 | 2018 | 6 | 0.150 |
Why?
| Protein Biosynthesis | 2 | 2017 | 254 | 0.150 |
Why?
| Hepatitis, Autoimmune | 1 | 2018 | 26 | 0.150 |
Why?
| Information Dissemination | 1 | 2019 | 79 | 0.150 |
Why?
| HSP72 Heat-Shock Proteins | 1 | 2018 | 8 | 0.150 |
Why?
| Treatment Outcome | 6 | 2019 | 5155 | 0.150 |
Why?
| Education, Nonprofessional | 1 | 2017 | 8 | 0.150 |
Why?
| Human Experimentation | 1 | 2017 | 11 | 0.150 |
Why?
| Sirtuin 1 | 1 | 2017 | 28 | 0.150 |
Why?
| Mass Screening | 1 | 2021 | 346 | 0.150 |
Why?
| Sulfonamides | 1 | 2019 | 128 | 0.150 |
Why?
| Teicoplanin | 1 | 2017 | 4 | 0.150 |
Why?
| Teaching Materials | 1 | 2017 | 31 | 0.150 |
Why?
| 3' Untranslated Regions | 1 | 2017 | 52 | 0.150 |
Why?
| Patient Participation | 1 | 2018 | 66 | 0.150 |
Why?
| Health Services Research | 1 | 2018 | 151 | 0.150 |
Why?
| Absorptiometry, Photon | 1 | 2018 | 153 | 0.150 |
Why?
| Rural Population | 2 | 2021 | 537 | 0.140 |
Why?
| Substance Abuse Detection | 2 | 2022 | 92 | 0.140 |
Why?
| Genetic Predisposition to Disease | 1 | 2020 | 509 | 0.140 |
Why?
| Reading | 1 | 2017 | 83 | 0.140 |
Why?
| Electrochemical Techniques | 1 | 2016 | 11 | 0.140 |
Why?
| Anthropometry | 2 | 2015 | 92 | 0.140 |
Why?
| Comprehension | 1 | 2017 | 110 | 0.140 |
Why?
| Age Factors | 3 | 2015 | 1092 | 0.140 |
Why?
| Nuclear Proteins | 1 | 2018 | 243 | 0.140 |
Why?
| Saliva | 1 | 2016 | 55 | 0.130 |
Why?
| Vitamin A | 1 | 2016 | 14 | 0.130 |
Why?
| Liver Failure | 1 | 2016 | 21 | 0.130 |
Why?
| Nitric Oxide Synthase Type I | 2 | 2015 | 10 | 0.130 |
Why?
| Amphetamine | 2 | 2013 | 38 | 0.130 |
Why?
| Point-of-Care Systems | 1 | 2016 | 56 | 0.130 |
Why?
| Blood Proteins | 2 | 2006 | 82 | 0.130 |
Why?
| Injections, Intravenous | 3 | 2012 | 143 | 0.130 |
Why?
| Caffeine | 1 | 2016 | 66 | 0.130 |
Why?
| Blood Pressure Monitors | 1 | 2015 | 10 | 0.130 |
Why?
| Biomedical Research | 1 | 2019 | 236 | 0.130 |
Why?
| Taurodeoxycholic Acid | 1 | 2015 | 6 | 0.130 |
Why?
| Glycodeoxycholic Acid | 1 | 2015 | 6 | 0.130 |
Why?
| Glycochenodeoxycholic Acid | 1 | 2015 | 6 | 0.130 |
Why?
| Guanidines | 1 | 2015 | 31 | 0.130 |
Why?
| Keratin-8 | 1 | 2015 | 3 | 0.130 |
Why?
| Styrene | 1 | 2015 | 9 | 0.130 |
Why?
| Bone Density | 1 | 2018 | 379 | 0.130 |
Why?
| Delayed-Action Preparations | 2 | 2012 | 51 | 0.130 |
Why?
| Prodrugs | 2 | 2012 | 32 | 0.130 |
Why?
| Solid Phase Extraction | 2 | 2013 | 11 | 0.130 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 72 | 0.130 |
Why?
| Tablets | 3 | 2013 | 31 | 0.130 |
Why?
| Breast Neoplasms | 1 | 2024 | 1179 | 0.120 |
Why?
| Cross-Over Studies | 2 | 2012 | 218 | 0.120 |
Why?
| Immunity, Innate | 1 | 2016 | 105 | 0.120 |
Why?
| Nitrates | 2 | 2011 | 27 | 0.120 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2014 | 2 | 0.120 |
Why?
| Administration, Intravenous | 3 | 2019 | 68 | 0.120 |
Why?
| Cells, Cultured | 4 | 2017 | 1581 | 0.120 |
Why?
| Environmental Pollutants | 1 | 2015 | 91 | 0.120 |
Why?
| Famotidine | 2 | 2005 | 11 | 0.120 |
Why?
| Discriminant Analysis | 1 | 2014 | 27 | 0.120 |
Why?
| Least-Squares Analysis | 1 | 2014 | 43 | 0.120 |
Why?
| Urinalysis | 1 | 2014 | 33 | 0.110 |
Why?
| Superoxide Dismutase | 2 | 2011 | 114 | 0.110 |
Why?
| Fentanyl | 1 | 2014 | 36 | 0.110 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2012 | 388 | 0.110 |
Why?
| Wounds, Stab | 1 | 2013 | 6 | 0.110 |
Why?
| Cannabis | 2 | 2019 | 145 | 0.110 |
Why?
| Cyclosporine | 2 | 2011 | 65 | 0.110 |
Why?
| Basal Ganglia | 1 | 2013 | 26 | 0.110 |
Why?
| Neck Injuries | 1 | 2013 | 21 | 0.110 |
Why?
| Benzoflavones | 1 | 2013 | 3 | 0.110 |
Why?
| Sulfaphenazole | 1 | 2013 | 4 | 0.110 |
Why?
| Nonlinear Dynamics | 2 | 2012 | 19 | 0.110 |
Why?
| Self-Injurious Behavior | 1 | 2013 | 27 | 0.110 |
Why?
| Cohort Studies | 3 | 2019 | 1422 | 0.110 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2012 | 485 | 0.110 |
Why?
| Kinetics | 4 | 2018 | 631 | 0.110 |
Why?
| Multidrug Resistance-Associated Proteins | 1 | 2012 | 16 | 0.110 |
Why?
| Mycophenolic Acid | 1 | 2012 | 18 | 0.110 |
Why?
| Myoglobin | 1 | 2013 | 25 | 0.110 |
Why?
| Receptors, Phospholipase A2 | 1 | 2012 | 14 | 0.110 |
Why?
| Neurotoxicity Syndromes | 1 | 2013 | 46 | 0.110 |
Why?
| Indicators and Reagents | 1 | 2012 | 37 | 0.110 |
Why?
| Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 26 | 0.100 |
Why?
| Dinoprostone | 1 | 2012 | 53 | 0.100 |
Why?
| Permeability | 1 | 2012 | 68 | 0.100 |
Why?
| Flushing | 1 | 2012 | 4 | 0.100 |
Why?
| Piperacillin | 1 | 2012 | 23 | 0.100 |
Why?
| Fasting | 1 | 2012 | 70 | 0.100 |
Why?
| Seroepidemiologic Studies | 2 | 2022 | 43 | 0.100 |
Why?
| Immunoglobulin Fab Fragments | 1 | 2012 | 16 | 0.100 |
Why?
| Blood Specimen Collection | 1 | 2012 | 34 | 0.100 |
Why?
| Erythema | 1 | 2012 | 38 | 0.100 |
Why?
| Insulin | 1 | 2014 | 456 | 0.100 |
Why?
| T-Lymphocytes | 1 | 2014 | 339 | 0.100 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 105 | 0.100 |
Why?
| Metronidazole | 1 | 2012 | 29 | 0.100 |
Why?
| Heart Septal Defects, Ventricular | 1 | 2012 | 41 | 0.100 |
Why?
| Exanthema | 1 | 2012 | 32 | 0.100 |
Why?
| Lipopolysaccharides | 1 | 2013 | 194 | 0.100 |
Why?
| Severity of Illness Index | 2 | 2012 | 951 | 0.100 |
Why?
| Pruritus | 1 | 2012 | 44 | 0.100 |
Why?
| Cardiopulmonary Bypass | 1 | 2012 | 91 | 0.100 |
Why?
| Ketamine | 1 | 2012 | 60 | 0.100 |
Why?
| Vancomycin | 1 | 2012 | 81 | 0.100 |
Why?
| Neutropenia | 1 | 2012 | 115 | 0.100 |
Why?
| Sex Factors | 1 | 2014 | 697 | 0.100 |
Why?
| Cellulitis | 1 | 2011 | 12 | 0.100 |
Why?
| Nitroimidazoles | 1 | 2011 | 15 | 0.090 |
Why?
| Anemia, Hemolytic | 1 | 2011 | 11 | 0.090 |
Why?
| Receptor, Cannabinoid, CB1 | 1 | 2012 | 125 | 0.090 |
Why?
| Neuroprotective Agents | 1 | 2012 | 103 | 0.090 |
Why?
| Rhabdomyolysis | 1 | 2011 | 12 | 0.090 |
Why?
| Hair | 1 | 2011 | 30 | 0.090 |
Why?
| Hypertension | 2 | 2015 | 537 | 0.090 |
Why?
| Anti-Inflammatory Agents | 1 | 2012 | 160 | 0.090 |
Why?
| Kidney Transplantation | 1 | 2012 | 175 | 0.090 |
Why?
| Coloring Agents | 1 | 2010 | 70 | 0.090 |
Why?
| Brain Injuries | 1 | 2012 | 157 | 0.090 |
Why?
| Muscular Diseases | 1 | 2011 | 61 | 0.090 |
Why?
| Interleukin-10 | 2 | 2012 | 84 | 0.090 |
Why?
| Liver Circulation | 1 | 2010 | 21 | 0.090 |
Why?
| Immunoblotting | 1 | 2010 | 117 | 0.090 |
Why?
| Play and Playthings | 1 | 2009 | 12 | 0.090 |
Why?
| Sodium Oxybate | 1 | 2009 | 11 | 0.090 |
Why?
| Coma | 1 | 2009 | 14 | 0.090 |
Why?
| Butylene Glycols | 1 | 2009 | 14 | 0.090 |
Why?
| Kidney Diseases | 1 | 2012 | 214 | 0.090 |
Why?
| Linear Models | 2 | 2012 | 278 | 0.090 |
Why?
| Blood Pressure | 1 | 2012 | 524 | 0.080 |
Why?
| Databases as Topic | 1 | 2009 | 37 | 0.080 |
Why?
| Immunosuppressive Agents | 1 | 2011 | 222 | 0.080 |
Why?
| Environmental Exposure | 1 | 2011 | 199 | 0.080 |
Why?
| Foreign Bodies | 1 | 2009 | 65 | 0.080 |
Why?
| Incidence | 1 | 2012 | 1006 | 0.080 |
Why?
| Drug Compounding | 1 | 2008 | 25 | 0.080 |
Why?
| Blood Chemical Analysis | 1 | 2008 | 27 | 0.080 |
Why?
| Registries | 2 | 2024 | 522 | 0.080 |
Why?
| Cesium | 1 | 2008 | 8 | 0.080 |
Why?
| Chlorides | 1 | 2008 | 50 | 0.080 |
Why?
| Probability | 1 | 2008 | 164 | 0.080 |
Why?
| Analgesics, Opioid | 1 | 2014 | 557 | 0.080 |
Why?
| Macrophages | 2 | 2017 | 363 | 0.080 |
Why?
| DNA | 1 | 2011 | 541 | 0.080 |
Why?
| Chloroform | 1 | 2007 | 5 | 0.080 |
Why?
| Models, Statistical | 1 | 2009 | 224 | 0.080 |
Why?
| Free Radical Scavengers | 2 | 2011 | 25 | 0.080 |
Why?
| Magnetic Resonance Imaging | 2 | 2012 | 1541 | 0.070 |
Why?
| Infusions, Intravenous | 2 | 2023 | 213 | 0.070 |
Why?
| Acute Kidney Injury | 1 | 2011 | 285 | 0.070 |
Why?
| Sulfuric Acids | 1 | 2006 | 8 | 0.070 |
Why?
| Electrocardiography | 1 | 2008 | 262 | 0.070 |
Why?
| Aerobiosis | 1 | 2006 | 14 | 0.070 |
Why?
| Genotype | 3 | 2018 | 534 | 0.070 |
Why?
| Analysis of Variance | 1 | 2007 | 564 | 0.070 |
Why?
| Emergency Medicine | 1 | 2006 | 52 | 0.070 |
Why?
| Hepatitis C, Chronic | 2 | 2018 | 83 | 0.070 |
Why?
| Toxicity Tests | 1 | 2006 | 54 | 0.070 |
Why?
| Antioxidants | 2 | 2023 | 241 | 0.060 |
Why?
| Reproducibility of Results | 3 | 2015 | 1185 | 0.060 |
Why?
| Phosphorylation | 2 | 2019 | 534 | 0.060 |
Why?
| Cell Nucleus | 1 | 2006 | 187 | 0.060 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 244 | 0.060 |
Why?
| Mice, Transgenic | 2 | 2018 | 550 | 0.060 |
Why?
| Metabolic Detoxication, Phase II | 2 | 2017 | 11 | 0.060 |
Why?
| Mitochondrial Membrane Transport Proteins | 1 | 2004 | 18 | 0.060 |
Why?
| Child Abuse | 1 | 2006 | 136 | 0.060 |
Why?
| Receptors, Progesterone | 1 | 2024 | 64 | 0.060 |
Why?
| Kupffer Cells | 1 | 2003 | 11 | 0.060 |
Why?
| Computer Simulation | 2 | 2017 | 280 | 0.060 |
Why?
| Risk Assessment | 1 | 2008 | 1262 | 0.060 |
Why?
| Glutathione Disulfide | 1 | 2003 | 41 | 0.060 |
Why?
| Single-Blind Method | 2 | 2015 | 115 | 0.060 |
Why?
| Models, Chemical | 2 | 2015 | 64 | 0.060 |
Why?
| Superoxides | 1 | 2003 | 46 | 0.060 |
Why?
| Alanine | 1 | 2023 | 42 | 0.060 |
Why?
| Pyruvic Acid | 1 | 2023 | 22 | 0.060 |
Why?
| Receptors, Estrogen | 1 | 2024 | 131 | 0.060 |
Why?
| Omeprazole | 1 | 2003 | 17 | 0.060 |
Why?
| Mixed Function Oxygenases | 1 | 2003 | 25 | 0.060 |
Why?
| Ischemia | 1 | 2024 | 153 | 0.060 |
Why?
| Injections, Intraperitoneal | 1 | 2003 | 55 | 0.060 |
Why?
| Prognosis | 3 | 2015 | 1954 | 0.060 |
Why?
| Safety | 1 | 2003 | 77 | 0.050 |
Why?
| Immunoenzyme Techniques | 1 | 2003 | 145 | 0.050 |
Why?
| Hydrogen Peroxide | 1 | 2003 | 115 | 0.050 |
Why?
| Oxygen | 1 | 2006 | 325 | 0.050 |
Why?
| Radiographic Image Enhancement | 1 | 2003 | 30 | 0.050 |
Why?
| Pediatrics | 1 | 2006 | 279 | 0.050 |
Why?
| Genetic Variation | 1 | 2024 | 213 | 0.050 |
Why?
| Tibial Fractures | 1 | 2003 | 32 | 0.050 |
Why?
| Logistic Models | 2 | 2018 | 889 | 0.050 |
Why?
| Drug Interactions | 1 | 2003 | 208 | 0.050 |
Why?
| Molecular Structure | 2 | 2013 | 296 | 0.050 |
Why?
| Membrane Potential, Mitochondrial | 2 | 2015 | 39 | 0.050 |
Why?
| Antibodies, Viral | 1 | 2022 | 88 | 0.050 |
Why?
| Hydroxylation | 2 | 2012 | 61 | 0.050 |
Why?
| Endothelium, Vascular | 1 | 2003 | 254 | 0.050 |
Why?
| Neoplasms | 1 | 2012 | 1249 | 0.050 |
Why?
| Glutamate Dehydrogenase | 1 | 2021 | 16 | 0.050 |
Why?
| Death, Sudden, Cardiac | 1 | 2022 | 57 | 0.050 |
Why?
| Psychotropic Drugs | 1 | 2022 | 77 | 0.050 |
Why?
| Nitric Oxide | 1 | 2003 | 254 | 0.050 |
Why?
| Databases, Factual | 1 | 2024 | 657 | 0.050 |
Why?
| Uncertainty | 1 | 2021 | 45 | 0.050 |
Why?
| Kidney Failure, Chronic | 1 | 2003 | 200 | 0.050 |
Why?
| Apoptosis | 1 | 2006 | 1112 | 0.040 |
Why?
| Gestational Age | 2 | 2012 | 418 | 0.040 |
Why?
| Anti-Asthmatic Agents | 1 | 2020 | 30 | 0.040 |
Why?
| Decision Making | 1 | 2002 | 267 | 0.040 |
Why?
| Australia | 1 | 2019 | 84 | 0.040 |
Why?
| Risk Factors | 3 | 2012 | 3629 | 0.040 |
Why?
| Research Design | 1 | 2021 | 342 | 0.040 |
Why?
| Drug Synergism | 1 | 2019 | 151 | 0.040 |
Why?
| Tissue Distribution | 2 | 2013 | 163 | 0.040 |
Why?
| Hepatitis Viruses | 1 | 2018 | 2 | 0.040 |
Why?
| Qualitative Research | 1 | 2021 | 336 | 0.040 |
Why?
| Metagenomics | 1 | 2018 | 40 | 0.040 |
Why?
| Mallory Bodies | 1 | 2018 | 1 | 0.040 |
Why?
| beta Catenin | 1 | 2019 | 102 | 0.040 |
Why?
| Drug Dosage Calculations | 1 | 2018 | 10 | 0.040 |
Why?
| Acute-Phase Reaction | 1 | 2018 | 8 | 0.040 |
Why?
| DNA, Viral | 1 | 2018 | 134 | 0.040 |
Why?
| RNA, Viral | 1 | 2018 | 126 | 0.040 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2018 | 77 | 0.040 |
Why?
| Ethics, Research | 1 | 2017 | 39 | 0.040 |
Why?
| Metabolic Networks and Pathways | 1 | 2018 | 89 | 0.040 |
Why?
| Gas Chromatography-Mass Spectrometry | 2 | 2011 | 67 | 0.040 |
Why?
| Metabolic Detoxication, Phase I | 1 | 2017 | 11 | 0.040 |
Why?
| MAP Kinase Signaling System | 1 | 2018 | 118 | 0.040 |
Why?
| Gene Frequency | 1 | 2017 | 94 | 0.040 |
Why?
| Glucuronides | 1 | 2017 | 45 | 0.040 |
Why?
| Plant Extracts | 1 | 2019 | 171 | 0.040 |
Why?
| Communication | 1 | 2019 | 246 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 170 | 0.040 |
Why?
| Rats | 2 | 2014 | 3299 | 0.040 |
Why?
| Residence Characteristics | 1 | 2017 | 149 | 0.030 |
Why?
| Liver Diseases, Alcoholic | 1 | 2016 | 35 | 0.030 |
Why?
| Oscillometry | 1 | 2015 | 8 | 0.030 |
Why?
| Sex Characteristics | 1 | 2017 | 191 | 0.030 |
Why?
| NAD | 1 | 2015 | 43 | 0.030 |
Why?
| Health Literacy | 1 | 2017 | 128 | 0.030 |
Why?
| Diastole | 1 | 2015 | 71 | 0.030 |
Why?
| Arm | 1 | 2015 | 47 | 0.030 |
Why?
| Systole | 1 | 2015 | 71 | 0.030 |
Why?
| Binding, Competitive | 1 | 2015 | 94 | 0.030 |
Why?
| Observer Variation | 1 | 2015 | 129 | 0.030 |
Why?
| Patient Safety | 1 | 2016 | 102 | 0.030 |
Why?
| Substrate Specificity | 1 | 2015 | 193 | 0.030 |
Why?
| Clinical Protocols | 1 | 2015 | 108 | 0.030 |
Why?
| Suramin | 1 | 2014 | 12 | 0.030 |
Why?
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2014 | 3 | 0.030 |
Why?
| Fas Ligand Protein | 1 | 2014 | 17 | 0.030 |
Why?
| Antigens, Ly | 1 | 2014 | 10 | 0.030 |
Why?
| Islets of Langerhans | 1 | 2014 | 24 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 181 | 0.030 |
Why?
| Oxygen Consumption | 1 | 2015 | 188 | 0.030 |
Why?
| Cell Proliferation | 1 | 2019 | 1013 | 0.030 |
Why?
| Glucose Tolerance Test | 1 | 2014 | 56 | 0.030 |
Why?
| Algorithms | 1 | 2018 | 618 | 0.030 |
Why?
| Gene Silencing | 1 | 2014 | 118 | 0.030 |
Why?
| Biological Availability | 2 | 2005 | 96 | 0.030 |
Why?
| Thiazolidinediones | 1 | 2014 | 82 | 0.030 |
Why?
| Brain | 2 | 2012 | 1328 | 0.030 |
Why?
| Paper | 1 | 2013 | 15 | 0.030 |
Why?
| Capsules | 1 | 2013 | 28 | 0.030 |
Why?
| Powders | 1 | 2013 | 22 | 0.030 |
Why?
| Pentanones | 1 | 2013 | 9 | 0.030 |
Why?
| Methylamines | 1 | 2013 | 17 | 0.030 |
Why?
| Glutathione Transferase | 1 | 2014 | 174 | 0.030 |
Why?
| Ethanol | 1 | 2016 | 341 | 0.030 |
Why?
| Body Temperature Regulation | 1 | 2013 | 24 | 0.030 |
Why?
| Fatal Outcome | 1 | 2013 | 195 | 0.030 |
Why?
| Hallucinogens | 1 | 2013 | 63 | 0.030 |
Why?
| Heterozygote | 1 | 2012 | 81 | 0.030 |
Why?
| Benzodioxoles | 1 | 2013 | 56 | 0.030 |
Why?
| Drug Resistance | 1 | 2012 | 64 | 0.030 |
Why?
| Cell Survival | 1 | 2014 | 602 | 0.030 |
Why?
| Pyrrolidines | 1 | 2013 | 83 | 0.030 |
Why?
| Placebo Effect | 1 | 2012 | 17 | 0.030 |
Why?
| Amine Oxidase (Copper-Containing) | 1 | 2012 | 3 | 0.030 |
Why?
| Pyrans | 1 | 2012 | 22 | 0.030 |
Why?
| Prescription Drugs | 1 | 2012 | 38 | 0.030 |
Why?
| Interleukin-3 | 1 | 2012 | 13 | 0.030 |
Why?
| Intention to Treat Analysis | 1 | 2012 | 27 | 0.030 |
Why?
| Calcitonin Gene-Related Peptide | 1 | 2012 | 22 | 0.030 |
Why?
| Disease Progression | 1 | 2015 | 831 | 0.030 |
Why?
| Histamine | 1 | 2012 | 25 | 0.030 |
Why?
| Glucose | 1 | 2014 | 338 | 0.030 |
Why?
| Protein Precursors | 1 | 2012 | 43 | 0.030 |
Why?
| Fever | 1 | 2013 | 115 | 0.030 |
Why?
| Calcitonin | 1 | 2012 | 30 | 0.030 |
Why?
| Insurance, Health, Reimbursement | 1 | 2012 | 24 | 0.030 |
Why?
| Dopamine | 1 | 2013 | 172 | 0.030 |
Why?
| Spectroscopy, Near-Infrared | 1 | 2012 | 53 | 0.030 |
Why?
| Population | 1 | 2012 | 8 | 0.030 |
Why?
| Office Visits | 1 | 2012 | 40 | 0.030 |
Why?
| Genetic Association Studies | 1 | 2012 | 116 | 0.030 |
Why?
| Ligands | 1 | 2012 | 205 | 0.030 |
Why?
| Expectorants | 1 | 2011 | 14 | 0.020 |
Why?
| Hyperthermia, Induced | 1 | 2013 | 117 | 0.020 |
Why?
| Risk | 1 | 2012 | 324 | 0.020 |
Why?
| Glucuronic Acid | 1 | 2011 | 8 | 0.020 |
Why?
| Creatinine | 1 | 2012 | 141 | 0.020 |
Why?
| Microsomes | 1 | 2011 | 35 | 0.020 |
Why?
| ROC Curve | 1 | 2012 | 232 | 0.020 |
Why?
| Monte Carlo Method | 1 | 2012 | 85 | 0.020 |
Why?
| Deuterium | 1 | 2011 | 43 | 0.020 |
Why?
| Central Nervous System | 1 | 2012 | 85 | 0.020 |
Why?
| Reference Standards | 1 | 2011 | 54 | 0.020 |
Why?
| Statistics as Topic | 1 | 2011 | 87 | 0.020 |
Why?
| Syndrome | 1 | 2012 | 238 | 0.020 |
Why?
| Birth Weight | 1 | 2012 | 120 | 0.020 |
Why?
| Cytoplasm | 1 | 2011 | 91 | 0.020 |
Why?
| Forensic Toxicology | 1 | 2011 | 5 | 0.020 |
Why?
| Muscular Dystrophies | 1 | 2011 | 15 | 0.020 |
Why?
| Glucuronidase | 1 | 2011 | 46 | 0.020 |
Why?
| Hair Color | 1 | 2011 | 10 | 0.020 |
Why?
| Spinal Muscular Atrophies of Childhood | 1 | 2011 | 9 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2012 | 143 | 0.020 |
Why?
| Crime | 1 | 2011 | 25 | 0.020 |
Why?
| Protein Isoforms | 1 | 2011 | 119 | 0.020 |
Why?
| Transaminases | 1 | 2011 | 11 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2012 | 581 | 0.020 |
Why?
| Staining and Labeling | 1 | 2011 | 97 | 0.020 |
Why?
| Forecasting | 1 | 2012 | 150 | 0.020 |
Why?
| Bilirubin | 1 | 2011 | 40 | 0.020 |
Why?
| Intensive Care Units | 1 | 2012 | 222 | 0.020 |
Why?
| Double-Blind Method | 1 | 2012 | 688 | 0.020 |
Why?
| Blotting, Western | 1 | 2011 | 601 | 0.020 |
Why?
| Intestines | 1 | 2011 | 168 | 0.020 |
Why?
| Child Development | 1 | 2012 | 191 | 0.020 |
Why?
| Intensive Care Units, Pediatric | 1 | 2011 | 167 | 0.020 |
Why?
| Intestinal Mucosa | 1 | 2011 | 215 | 0.020 |
Why?
| Body Mass Index | 1 | 2013 | 656 | 0.020 |
Why?
| Suction | 1 | 2009 | 24 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2013 | 1586 | 0.020 |
Why?
| Alcohol Drinking | 1 | 2011 | 226 | 0.020 |
Why?
| Eating | 1 | 2009 | 161 | 0.020 |
Why?
| Kidney | 1 | 2013 | 672 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 2011 | 466 | 0.020 |
Why?
| Survival Rate | 1 | 2011 | 901 | 0.020 |
Why?
| Alcoholism | 1 | 2011 | 233 | 0.020 |
Why?
| Nitric Oxide Synthase | 1 | 2007 | 75 | 0.020 |
Why?
| Muscle, Skeletal | 1 | 2013 | 765 | 0.020 |
Why?
| Carcinoma, Hepatocellular | 1 | 2008 | 193 | 0.020 |
Why?
| Liver Neoplasms | 1 | 2008 | 328 | 0.010 |
Why?
| Follow-Up Studies | 1 | 2009 | 2190 | 0.010 |
Why?
| Electrophoresis, Gel, Pulsed-Field | 1 | 2003 | 29 | 0.010 |
Why?
| Specialization | 1 | 2003 | 46 | 0.010 |
Why?
| Medicine | 1 | 2003 | 56 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 2003 | 454 | 0.010 |
Why?
| Endopeptidases | 1 | 2002 | 66 | 0.010 |
Why?
|
|
James's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|